NCT02206646View on ClinicalTrials.gov

Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction

CompletedOBSERVATIONAL
Enrollment

987

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 28, 2009

Conditions
Myocardial Infarction
Interventions
DRUG

Metalyse

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02206646 - Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter